Phosphorylated heterodimers of ERBB2 TMD/JMD mutants phosphorylate SHC1

Stable Identifier
R-HSA-9665705
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Activation of downstream RAS signaling was shown for ERBB2 S653C (de Martino et al. 2014) and ERBB2 R678Q (Bose et al. 2013, de Martino et al. 2014) through activating tyrosine phosphorylation on ERKs (MAPK1 and MAPK3) and SHC1. It is assumed that heterodimers of ERBB2 TMD/JMD mutants, like the wild type ERBB2 heterodimers, bind to and phosphorylate SHC1.

Literature References
PubMed ID Title Journal Year
23220880 Activating HER2 mutations in HER2 gene amplification negative breast cancer

Bose, R, Kavuri, SM, Searleman, AC, Shen, W, Shen, D, Koboldt, DC, Monsey, J, Goel, N, Aronson, AB, Li, S, Ma, CX, Ding, L, Mardis, ER, Ellis, MJ

Cancer Discov 2013
24971884 Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib

de Martino, M, Zhuang, D, Klatte, T, Rieken, M, RouprĂȘt, M, Xylinas, E, Clozel, T, Krzywinski, M, Elemento, O, Shariat, SF

Cancer Biol. Ther. 2014
Participants
Participates
Catalyst Activity

protein tyrosine kinase activity of p-6Y-ERBB2 TMD/JMD mutants (RAS):Ligand-Activated p-EGFR,p-ERBB3,(p-ERBB4):SHC1 [plasma membrane]

Normal reaction
Functional status

Gain of function of p-6Y-ERBB2 TMD/JMD mutants (RAS):Ligand-Activated p-EGFR,p-ERBB3,(p-ERBB4):SHC1 [plasma membrane]

Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!